on behalf of the CYCLE Investigators ABSTRACT BACKGROUND Whether cyclosporine A (CsA) has beneficial effects in reperfused myocardial infarction (MI) is debated.
Experimental evidence suggests that different interventions designed to prevent mPTP opening may reduce myocardial infarct size by an additional 30% to 50% in various animal models (9) . A single intravenous bolus of cyclosporine A (CsA) before reperfusion was reported to reduce creatine kinase (CK) release by 40% in 58 STEMI patients treated with primary percutaneous coronary interventions (pPCI) (10) , and to attenuate the impairment of left ventricular (LV) function over 6 months after myocardial infarction (MI) in the same patients (11) . This proof-of-concept study created new enthusiasm in targeting reperfusion for cardiac protection, with CsA as prototypical agent (12, 13) , while also paving the way to a larger multicenter study to verify these very encouraging findings, before proceeding to a trial on "hard" clinical endpoints. However, a double-blind trial in 101 STEMI patients showed that CsA given right before thrombolysis neither reduced MI size nor improved clinical outcomes (14) . Ottani et al.
antecubital vein after coronary angiography, but just before passage of the wire into the culprit artery (thus avoiding any wire-related dissolution/fragmentation of the occlusive thrombus), and at least 5 min before PCI, to allow distribution of the drug. In the control group, patients received only recommended treatments according to STEMI European guidelines (3).
Coronary angiography was then done using standard techniques to identify the culprit coronary artery and to check that reperfusion had not occurred before PCI The primary efficacy endpoint was the incidence of $70% resolution of ST-segment elevation 1 h after pPCI, as previously described (18, 19) . This was due to the assumption that in addition to being a On the basis of previous data (18) a 55% incidence of the primary endpoint was assumed in the placebo arm. We calculated that 444 patients (222 patients per group) were required for the study to have 80%
Ottani et al. In all, 80% were male, 40% were active smokers, and 14% had diabetes. More than one-half of the population was hypertensive. Pre-infarction angina within 48 h before the index event was reported in approximately one-half of the patients ( Table 1) . Ottani et al.
The 2 groups had a similar hemodynamic status, depicted by blood pressure, heart rate, and Killip class. They were also comparable for all major events occurring before randomization (i.e., defibrillation, and maximum pressure of the balloon inflation, did not differ between the 2 groups (Online Table 1 Table 1 ). Table 1 ). Clinical events over the 6-month follow up are reported in Table 3 ).
SAFETY. Great care was taken to monitor patients in the first few hours after the index event for rare acute reactions to intravenous CsA, which have been reported and attributed to 1 of the excipients, ricinoleic acid (24) (25) (26) . In fact, no anaphylactoid reactions were reported during the CYCLE trial. Only 1 serious adverse drug reaction was reported in the whole trial, a patient in the CsA group who died after surgery for myocardial rupture 23 days after the index MI (Table 3) . The present study is not the first to show the failure of agents targeted to reperfusion injury for cardioprotection (28) . In other cases, some acute protective action was apparent, which did not appear to lead to substantial long-term benefits (29, 30) .
Cardioprotective effects leading to long-term benefit on cardiac function have been shown only for ischemic conditioning (31) (32) (33) and for a beta-blocker, metoprolol (34, 35) . Ottani et al. Cyclosporine A in Reperfused STEMI
